Bladder Cancer Weekly

June 01, 2026

Videos

Peer-to-Peer Clinical Conversations

SunRISe-1 Cohort 4 Analysis: One-Year Disease-Free Survival in BCG-Unresponsive Papillary Bladder Cancer - Siamak Daneshmand

Siamak Daneshmand

Siamak Daneshmand presents SunRISe-1 Cohort 4 one-year results for gemcitabine intravesical system (Gem-iDRS), INLEXZO™ (gemcitabine intravesical system; formerly TAR-200) in BCG-unresponsive papillary NMIBC.

View

Design and Safety of a Patient-Centric Expanded Access Program with Cretostimogene Grenadenorepvec - Sarah Psutka

Sarah Psutka

Sarah Psutka discusses cretostimogene grenadenorepvec expanded access program with Ashish Kamat.

View

Beyond the Abstracts

Bacillus Calmette-Guérin Plus Mitomycin versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301) - Beyond the Abstract

A Multi-Modal Approach for Decision Making in Bladder Cancer - Beyond the Abstract

Conference Coverage

ASCO 2026: Disitamab Vedotin Combined with Toripalimab and Pelvic Lymph Node Dissection for Bladder Preservation in Patients with cT2-4aN0M0 Bladder Urothelial Carcinoma and HER2 Expression ≥ 2+ After Maximal TURBT

ASCO 2026: A Phase III Randomized Trial of Pembrolizumab in Combination with Sactizumab Govitecan vs Standard of Care in Ant-PD-(L)1-Resistant aUC: ECOG ACRIN EA8231

ASCO 2026: Final Results from a Phase II Study of Tislelizumab Combined with RT as Bladder Preserving Treatment for High-Risk NMIBC Patients with Unresponsive BCG

ASCO 2026: Interim Analysis Results from Duravelo-2: Zelenectide Pevedotin in Patients with Previously Treated la/mUC

ASCO 2026: RNDO-564-001: A First-in-Human, Phase 1/1b Study of RNDO-564, a Costimulatory Bispecific Antibody for the Treatment of Advaned Bladder Cancer and Other Nectin-4-Positive Solid Tumors

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Decoding Immune Mechanisms in BCG-unresponsive Non-muscle Invasive Bladder Cancer.

Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Expert Consensus.

AI-MIRACLE: Artificial Intelligence and MultIpaRAmetric MRI Predict CLinical OutcomEs to Neoadjuvant Immunotherapy in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy.

Computed tomography-derived extracellular volume fraction is associated with high-grade recurrence in non-muscle-invasive bladder cancer treated with intravesical gemcitabine and docetaxel.

Real-world Patterns and Trends of Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer: Insights from a Large Prospective German Cohort.

Durvalumab and BCG Approved for Treating High-Risk NMIBC

Trends in the diagnosis of variant bladder cancer: a national retrospective cohort analysis.

Proceedings of the first international NMIBC consensus classification meeting.

Diagnostic performance of urinary tumor DNA in urothelial carcinoma: A systematic review and network meta-analysis.

Effective PD-1 checkpoint blockade in bladder cancer model requires tumor-draining lymph nodes and lymphocyte trafficking.

Outcomes for females versus males treated with eribulin mesylate for advanced urothelial carcinoma.

Artificial Intelligence Remote Patient Monitoring for Predicting Overall Survival for Patients Undergoing Radical Cystectomy for Bladder Cancer: Exploratory Analysis of the Prospective Trial.

Real-world Outcomes of Adjuvant Nivolumab in High-risk Bladder and Upper Tract Urothelial Carcinoma after Radical Surgery.

Detection of Bladder Cancer in Patients with Microscopic Hematuria Using Oncuria-Detect: Results of a Prospective, Multicenter International Study - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Bladder Cancer Weekly

Bladder Cancer

Login